
An extension of a long-acting cabotegravir study shows safety prior to and during pregnancy in cisgender women, with full results being presented at the 2024 International AIDS Conference.
An extension of a long-acting cabotegravir study shows safety prior to and during pregnancy in cisgender women, with full results being presented at the 2024 International AIDS Conference.
Adherence and efficacy were both higher in patients with HIV who took twice-yearly lenacapavir compared to those on oral preexposure prophylaxis medication.